HBV carrying drug-resistance mutations in chronically infected treatment-naive patients

Imagem de Miniatura
Arquivos
art_GOMES-GOUVEA_HBV_carrying_drugresistance_mutations_in_chronically_infected_treatmentnaive_2015(1).PDF (259.84 KB)
Citações na Scopus
32
Tipo de produção
article
Data de publicação
2015
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
INT MEDICAL PRESS LTD
Autores
TEIXEIRA, Rosangela
ANDRADE, Jose R.
FERREIRA, Adalgisa S. P.
BARROS, Lena M. F.
REZENDE, Rosamar E. F.
LEITE, Andrea G. B.
PICCOLI, Leonora Z.
Citação
ANTIVIRAL THERAPY, v.20, n.4, p.387-395, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Nucleoside/nucleotide analogue (NA) treatment causes selection pressure for HBV strains carrying mutations conferring NA resistance. Drug-resistance mutations occur in the reverse transcriptase (RT) region of the HBV polymerase gene and spontaneously arise during viral replication. These mutations can also alter the hepatitis B surface (HBs) protein and in some cases reduce binding to HBs antibodies. The spread of NA-resistant HBV may impact the efficacy of antiviral treatment and hepatitis B immunization programmes. In this study, we used direct sequencing to assess the occurrence of HBV carrying known mutations that confer NA resistance in the largest cohort of treatment-naive patients with chronic hepatitis B (CHB) to date. Methods: HBV DNA samples isolated from 702 patients were sequenced and the RT region subjected to mutational analysis. Results: There was high genetic variability among the HBV samples analysed: A1 (63.7%), D3 (14.5%), A2 (3.3%), A3 (0.1%), B1 (0.1%), B2 (0.1%), C2 (0.9%), D1 (0.9%), D2 (4.6%), D4 (5.1%), D unclassified sub-genotype (0.7%), E (0.6%), F2a (4.6%), F4 (0.4%) and G (0.4%). HBV strains harbouring mutations conferring NA resistance alone or combined with compensatory mutations were identified in 1.6% (11/702) of the patients. Conclusions: HBV strains harbouring resistance mutations can comprise the major population of HBV quasispecies in treatment-naive patients. In Brazil, there is a very low frequency of untreated patients who are infected with these strains. These findings suggest that the spread and natural selection of drug-resistant HBV is an uncommon event and/or most of these strains remain unstable in the absence of NA selective pressure.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/11660
Referências
  1. Amini-Bavil-Olyaee S, 2009, J HEPATOL, V51, P647, DOI 10.1016/j.jhep.2009.04.022
  2. Bartholorneusz A, 2006, SEMIN LIVER DIS, V26, P162, DOI 10.1055/s-2006-939758
  3. Borroto-Esoda K, 2007, J HEPATOL, V47, P492, DOI 10.1016/j.jhep.2007.06.011
  4. Bottecchia M, 2008, J ANTIMICROB CHEMOTH, V62, P626, DOI 10.1093/jac/dkn207
  5. Curtis M, 2007, J INFECT DIS, V196, P1483, DOI 10.1086/522521
  6. Delaney WE, 2003, J VIROL, V77, P11833, DOI 10.1128/JVI.77.21.11833-11841-2003
  7. De Maddalena C, 2007, VIROLOGY, V365, P113, DOI 10.1016/j.virol.2007.03.015
  8. Estevez MA, 2013, ENFERM INFEC MICR CL, V31, P520, DOI 10.1016/j.eimc.2013.02.014
  9. Han Y, 2009, J GASTROEN HEPATOL, V24, P1417, DOI 10.1111/j.1440-1746.2009.05864.x
  10. Ismail AM, 2012, INTERVIROLOGY, V55, P36, DOI 10.1159/000323521
  11. Jardi R, 2007, J VIRAL HEPATITIS, V14, P835, DOI 10.1111/j.1365-2893.2007.00877.x
  12. Kamili S, 2009, HEPATOLOGY, V49, P1483, DOI 10.1002/hep.22796
  13. Karatayli E, 2012, J CLIN VIROL, V53, P130, DOI 10.1016/j.jcv.2011.10.011
  14. Khudyakov Y, 2010, ANTIVIR THER, V15, P505, DOI 10.3851/IMP1515
  15. Lee YS, 2012, J GASTROEN HEPATOL, V27, P300, DOI 10.1111/j.1440-1746.2011.06853.x
  16. Li XG, 2012, J MED VIROL, V84, P207, DOI 10.1002/jmv.23182
  17. Liu BM, 2010, ANTIVIR RES, V85, P512, DOI 10.1016/j.antiviral.2009.12.006
  18. Liu LJ, 2010, J VIRAL HEPATITIS, V17, P66, DOI 10.1111/j.1365-2893.2010.01273.x
  19. Lok AS, 2007, HEPATOLOGY, V46, P254, DOI 10.1002/hep.21698
  20. Lok ASF, 2009, HEPATOLOGY, V50, P661, DOI 10.1002/hep.23190
  21. Mantovani N, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-320
  22. Margeridon-Thermet S, 2013, ANTIMICROB AGENTS CH, V57, P343, DOI 10.1128/AAC.01601-12
  23. Mello FCA, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-96
  24. Mello FCA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-103
  25. Mello FCD, 2012, MEM I OSWALDO CRUZ, V107, P317, DOI 10.1590/S0074-02762012000300005
  26. Ministerio da Saude Departamento de DST, 2011, VIR HEP BRAZ STAT AC
  27. Ministerio da Saude Departamento de DST Aids e Hepatites Virais, 2011, CLIN PROT THER GUID
  28. Mohebbi SR, 2012, J MED VIROL, V84, P414, DOI 10.1002/jmv.23200
  29. Morando F, 2013, J MED VIROL, V85, P210, DOI 10.1002/jmv.23448
  30. Nguyen MH, 2009, ALIMENT PHARM THER, V30, P1150, DOI 10.1111/j.1365-2036.2009.04151.x
  31. Pereira LMMB, 2009, AM J TROP MED HYG, V81, P240
  32. Pollicino T, 2009, ANTIVIR THER, V14, P649
  33. Qin B, 2013, CHINESE SCI BULL, V58, P1760, DOI 10.1007/s11434-013-5770-x
  34. Salpini R, 2011, ANTIVIR RES, V92, P382, DOI 10.1016/j.antiviral.2011.08.013
  35. Sayan M, 2011, INT J INFECT DIS, V15, pE722, DOI 10.1016/j.ijid.2011.05.019
  36. Sayan M, 2010, INT J INFECT DIS, V14, pE136, DOI 10.1016/j.ijid.2009.11.039
  37. Sayan M, 2010, J VIRAL HEPATITIS, V17, P23, DOI 10.1111/j.1365-2893.2009.01149.x
  38. Schildgen O, 2010, J CLIN MICROBIOL, V48, P631, DOI 10.1128/JCM.01073-09
  39. Selabe SG, 2007, J MED VIROL, V79, P1650, DOI 10.1002/jmv.20974
  40. Sheldon J, 2006, J VIRAL HEPATITIS, V13, P427, DOI 10.1111/j.1365-2893.2005.00713.x
  41. Singla B, 2013, J MED VIROL, V85, P1155, DOI 10.1002/jmv.23608
  42. Sitnik R, 2010, REV INST MED TROP SP, V52, P119, DOI [10.1590/50036-46652010000300001, 10.1590/S0036-46652010000300001]
  43. Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
  44. Te Helen S, 2010, Clin Liver Dis, V14, P1, DOI 10.1016/j.cld.2009.11.009
  45. Tenney DJ, 2004, ANTIMICROB AGENTS CH, V48, P3498, DOI 10.1128/AAC.48.9.3498-3507.2004
  46. Thio CL, 2013, AIDS, V27, P191, DOI 10.1097/QAD.0b013e32835a9984
  47. Torresi J, 2002, VIROLOGY, V293, P305, DOI 10.1006/viro.2001.1246
  48. Trevino A, 2009, AIDS RES HUM RETROV, V25, P1273, DOI 10.1089/aid.2009.0119
  49. Xu ZH, 2010, J CLIN VIROL, V48, P270, DOI 10.1016/j.jcv.2010.05.010
  50. Yeh CT, 2010, ANTIVIR THER, V15, P471, DOI 10.3851/IMP1552
  51. Zheng JX, 2012, LIVER INT, V32, P1535, DOI 10.1111/j.1478-3231.2012.02859.x
  52. Zoulim F, 2009, GASTROENTEROLOGY, V137, P1593, DOI 10.1053/j.gastro.2009.08.063

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/06
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - ODS/03